Advertisement
Screener

REGENERON PHARMACEUTICALS, INC. (REGN) Investment Income, Nonoperating

2.8 / 5 stars · 68/120 Roast Me

REGENERON PHARMACEUTICALS, INC. Investment Income, Nonoperating

REGENERON PHARMACEUTICALS, INC. (REGN) reported Investment Income, Nonoperating of $3.30 million for the 3-month period ending 2016-09-30, per its 10-Q filed 2016-11-04.

Discontinued › Income Statement › Other Income

us-gaap:InvestmentIncomeNonoperating · last filed 2016-11-04

  • REGENERON PHARMACEUTICALS, INC. investment income, nonoperating for the quarter ending 2016-09-30 was $3.30M, a 54.25% increase year-over-year.
  • REGENERON PHARMACEUTICALS, INC. investment income, nonoperating for the quarter ending 2016-06-30 was $2.80M, a 69.45% increase year-over-year.
  • REGENERON PHARMACEUTICALS, INC. investment income, nonoperating for the quarter ending 2016-03-31 was $2.25M, a 1149.44% increase year-over-year.
  • REGENERON PHARMACEUTICALS, INC. investment income, nonoperating for the quarter ending 2015-09-30 was $2.14M.
  • REGENERON PHARMACEUTICALS, INC. investment income, nonoperating for fiscal 2013 was -$231.00K, a 111.48% decline from fiscal 2012.
  • REGENERON PHARMACEUTICALS, INC. investment income, nonoperating for fiscal 2012 was $2.01M, a 43.31% decline from fiscal 2011.
  • REGENERON PHARMACEUTICALS, INC. investment income, nonoperating for fiscal 2011 was $3.55M, a 67.25% increase from fiscal 2010.
  • REGENERON PHARMACEUTICALS, INC. investment income, nonoperating for fiscal 2010 was $2.12M, a 52.72% decline from fiscal 2009.
Period endInvestment Income, Nonoperating 3 monthInvestment Income, Nonoperating 6 monthInvestment Income, Nonoperating 9 monthInvestment Income, Nonoperating 12 month
2016-09-30$3.30M
10-Q · filed 2016-11-04
$6.10M
derived: sum of 2 quarters · filed 2016-11-04
$8.35M
10-Q · filed 2016-11-04
2016-06-30$2.80M
10-Q · filed 2016-08-04
$5.05M
10-Q · filed 2016-08-04
2016-03-31$2.25M
10-Q · filed 2016-05-05
2015-09-30$2.14M
10-Q · filed 2016-11-04
$3.79M
derived: sum of 2 quarters · filed 2016-11-04
$3.97M
10-Q · filed 2016-11-04
2015-06-30$1.65M
10-Q · filed 2016-08-04
$1.83M
10-Q · filed 2016-08-04
2015-03-31$180.00K
10-Q · filed 2016-05-05
2014-06-30$1.68M
10-Q · filed 2014-08-05
$2.61M
10-Q · filed 2014-08-05
$355.00K
derived: sum of 3 quarters · filed 2014-08-05
$973.00K
derived: sum of 4 quarters · filed 2014-08-05
2014-03-31$937.00K
10-Q · filed 2014-05-08
-$1.32M
derived: sum of 2 quarters · filed 2014-05-08
-$704.00K
derived: sum of 3 quarters · filed 2014-05-08
$250.00K
derived: sum of 4 quarters · filed 2014-08-05
2013-12-31-$2.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13
-$1.64M
derived: sum of 2 quarters · filed 2014-02-13
-$687.00K
derived: sum of 3 quarters · filed 2014-08-05
-$231.00K
10-K · filed 2014-02-13
2013-09-30$618.00K
10-Q · filed 2013-11-05
$1.57M
derived: sum of 2 quarters · filed 2014-08-05
$2.03M
10-Q · filed 2013-11-05
$2.41M
derived: sum of 4 quarters · filed 2014-08-05
2013-06-30$954.00K
10-Q · filed 2014-08-05
$1.41M
10-Q · filed 2014-08-05
$1.79M
derived: sum of 3 quarters · filed 2014-08-05
$2.31M
derived: sum of 4 quarters · filed 2014-08-05
2013-03-31$456.00K
10-Q · filed 2014-05-08
$840.00K
derived: sum of 2 quarters · filed 2014-05-08
$1.36M
derived: sum of 3 quarters · filed 2014-05-08
$1.86M
derived: sum of 4 quarters · filed 2014-05-08
2012-12-31$384.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13
$901.00K
derived: sum of 2 quarters · filed 2014-02-13
$1.40M
derived: sum of 3 quarters · filed 2014-02-13
$2.01M
10-K · filed 2014-02-13
2012-09-30$517.00K
10-Q · filed 2013-11-05
$1.02M
derived: sum of 2 quarters · filed 2013-11-05
$1.63M
10-Q · filed 2013-11-05
$2.43M
derived: sum of 4 quarters · filed 2014-02-13
2012-06-30$501.00K
10-Q · filed 2013-08-06
$1.11M
10-Q · filed 2013-08-06
$1.91M
derived: sum of 3 quarters · filed 2014-02-13
$2.63M
derived: sum of 4 quarters · filed 2014-02-13
2012-03-31$610.00K
10-Q · filed 2013-05-03
$1.41M
derived: sum of 2 quarters · filed 2014-02-13
$2.12M
derived: sum of 3 quarters · filed 2014-02-13
$3.12M
derived: sum of 4 quarters · filed 2014-02-13
2011-12-31$799.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13
$1.51M
derived: sum of 2 quarters · filed 2014-02-13
$2.51M
derived: sum of 3 quarters · filed 2014-02-13
$3.55M
10-K · filed 2014-02-13
2011-09-30$715.00K
10-Q · filed 2012-10-24
$1.71M
derived: sum of 2 quarters · filed 2012-10-24
$2.75M
10-Q · filed 2012-10-24
$3.39M
derived: sum of 4 quarters · filed 2013-02-15
2011-06-30$998.00K
10-Q · filed 2012-07-25
$2.04M
10-Q · filed 2012-07-25
$2.67M
derived: sum of 3 quarters · filed 2013-02-15
$3.13M
derived: sum of 4 quarters · filed 2013-02-15
2011-03-31$1.04M
10-Q · filed 2012-04-26
$1.68M
derived: sum of 2 quarters · filed 2013-02-15
$2.13M
derived: sum of 3 quarters · filed 2013-02-15
$2.72M
derived: sum of 4 quarters · filed 2013-02-15
2010-12-31$638.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15
$1.09M
derived: sum of 2 quarters · filed 2013-02-15
$1.68M
derived: sum of 3 quarters · filed 2013-02-15
$2.12M
10-K · filed 2013-02-15
2010-09-30$453.00K
10-Q · filed 2011-10-27
$1.04M
derived: sum of 2 quarters · filed 2011-10-27
$1.48M
10-Q · filed 2011-10-27
$2.04M
derived: sum of 4 quarters · filed 2012-02-21
2010-06-30$592.00K
10-Q · filed 2011-07-28
$1.03M
10-Q · filed 2011-07-28
$1.58M
derived: sum of 3 quarters · filed 2012-02-21
$2.44M
derived: sum of 4 quarters · filed 2012-02-21
2010-03-31$439.00K
10-Q · filed 2011-05-03
$992.00K
derived: sum of 2 quarters · filed 2012-02-21
$1.85M
derived: sum of 3 quarters · filed 2012-02-21
$3.18M
derived: sum of 4 quarters · filed 2012-02-21
2009-12-31$553.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21
$1.41M
derived: sum of 2 quarters · filed 2012-02-21
$2.74M
derived: sum of 3 quarters · filed 2012-02-21
$4.49M
10-K · filed 2012-02-21
2009-09-30$857.00K
10-Q · filed 2010-10-28
$2.19M
derived: sum of 2 quarters · filed 2010-10-28
$3.94M
10-Q · filed 2010-10-28
2009-06-30$1.33M
10-Q · filed 2010-07-28
$3.08M
10-Q · filed 2010-07-28
2008-12-31$18.16M
10-K · filed 2011-02-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07